A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
← catalyst calendarSponsored by Ocular Therapeutix, Inc. (industry) · OCUL — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
83actual
Sites
30
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-03
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-16 | actual | When the study began enrolling |
| Primary completion | 2024-01-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-01-24 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-19 | actual | When this record first appeared on the registry |
| Results posted | 2026-09-03 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
- Drug: OTX-TIC low dose Travoprost Intracameral Implant
- Drug: OTX-TIC high dose Travoprost Intracameral Implant
- Drug: Durysta, Bimatoprost Intracameral Implant 10 µg
Primary outcome
what the primary-completion date above is the date OFIOP Changes From Baseline in the Study Eye
measured Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-01-22 · 4.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-01-26 · 3.2 MB · SAP_001.pdf
Related
OCUL · their whole pipeline · Glaucoma readouts
OCUL's other studiesmost recently updated first
- Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study Phase 3 · Recruiting
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy Phase 3 · Recruiting
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration Phase 3 · Active, not recruiting
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration Phase 3 · Active, not recruiting
- CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension Phase 1 · Completed
Permalink · OCUL's whole pipeline · Catalyst calendar · Every registered study · What changed